Additional analysis of Phase II safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC

Additional analysis of Phase II safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC - LOGiK1401-A

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017806

Enrollment

Registered

2015-06-04

Start date

2015-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cance

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled onto the Phase II safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC (UMIN000015094) 2) Patients whose plasma sample can be obtained at day 15 3) Patients providing written informed consent.

Exclusion criteria

Exclusion criteria: Nothing particular

Design outcomes

Primary

Measure	Time frame
To explore the relationship between dose and safety/efficacy of alectinib	—

Countries

Japan

Contacts

Public ContactEiji Iwama

Graduate School of Medical Sciences, Kyushu University Faculty of Medical Sciences, Department of Comprehensive Clinical Oncology

iwama@kokyu.med.kyushu-u.ac.jp092-642-5378

Outcome results